Deals this week: Repligen, CoBe Capital, Chembio Diagnostics

29 June 2017 (Last Updated June 29th, 2017 18:30)

US-based bioprocessing company Repligen Corp has announced a public offering of 2,807,017 shares priced at $42.75 each, to raise $120m.

US-based bioprocessing company Repligen Corp has announced a public offering of 2,807,017 shares priced at $42.75 each, to raise $120m.

The company plans to use the funds towards working capital and general corporate requirements, including possible acquisitions, products and technologies.

US-based private equity firm CoBe Capital LLC plans to acquire Hill-Rom Holdings’ Volker business.

The divestiture will enable Hill-Rom to enhance its portfolio and focus on key growth platforms.

"The divestiture will enable Hill-Rom to enhance its portfolio and focus on key growth platforms."

Chembio Diagnostics Inc plans to issue common stock shares to raise $21.2m.

The US-based point-of-care diagnostic tests developer plans to use the stocks for general corporate purposes.

Glooko Inc has secured $35m through a series C financing round led by Georgian Partners.

Glooko, a US-based patient monitoring platform provider for diabetes, plans to use the funds to expand its market presence.